Diabetic Peripheral Neuropathy Market Report 2026

Diabetic Peripheral Neuropathy Market Overview

• Diabetic Peripheral Neuropathy market size has reached to $3.83 billion in 2025 • Expected to grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Increase In Obesity-Related Health Issues Propelling Growth In The Market • Market Trend: Advancements In Non-Opioid Pain Treatments For Neuropathy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Diabetic Peripheral Neuropathy Market?

Diabetic Peripheral Neuropathy (DPN) is a nerve disorder caused by prolonged high blood sugar levels in individuals with diabetes, leading to nerve damage primarily in the legs, feet, arms, and hands. This condition occurs due to long-term high blood sugar levels, which damage the nerves and blood vessels, impairing nerve function and blood flow to the affected areas. The main types of diabetic peripheral neuropathy are type 2 diabetic peripheral neuropathy and type 1 diabetic peripheral neuropathy. Type 2 diabetic peripheral neuropathy is a nerve damage condition caused by prolonged high blood sugar levels in type 2 diabetes, leading to pain, numbness, and tingling, primarily in the feet and hands. Treatment options include pain management drugs and emerging gene therapies, while therapeutic approaches involve the use of antidepressants and anticonvulsants. The patient population affected by diabetic peripheral neuropathy primarily includes adult and geriatric patients.

What Is The Diabetic Peripheral Neuropathy Market Growth Forecast?

The diabetic peripheral neuropathy market size is expected to see strong growth in the next few years. It will grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to improved screening technologies, expansion of specialty care centers, development of novel pain therapies, increased patient education, rising elderly diabetic population. Major trends in the forecast period include growing demand for peripheral neuropathy therapies, increased focus on early sensory loss detection, expansion of combination pain management treatments, rising adoption of long-term symptom control therapies, increased patient screening and monitoring.

Global Diabetic Peripheral Neuropathy Market Segmentation

1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy 2) By Treatment: Pain Management Drugs, Gene Therapies 3) By Therapy: Antidepressants, Anticonvulsants 4) By Patient Population: Adult Patients, Geriatric Patients Subsegments: 1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy 2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy

What Is The Driver Of The Diabetic Peripheral Neuropathy Market?

The increase in obesity-related health issues is expected to propel the growth of the diabetic peripheral neuropathy market going forward. Obesity is a medical condition characterized by excessive body fat accumulation that may impair health and increase the risk of various chronic diseases. The increase in obesity-related health issues is due to rising awareness, lifestyle changes, and a growing need for preventive and treatment solutions, leading to increased healthcare demand. Diabetic peripheral neuropathy is helpful for obesity management. It provides critical insights into nerve damage caused by obesity-related conditions, guiding targeted interventions to improve overall patient well-being and quality of life. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, 23 states reported adult obesity prevalence of 35% or higher in 2023, and all 50 states recorded obesity rates of at least 20%. Therefore, the increase in obesity-related health issues is driving growth in the diabetic peripheral neuropathy industry.

Key Players In The Global Diabetic Peripheral Neuropathy Market

Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., NeuroMetrix Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca plc., Bayer AG., UCB SA., Regeneron Pharmaceuticals Inc., Roche., Sanofi S.A., Amgen Inc., Lexicon Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd.

Global Diabetic Peripheral Neuropathy Market Trends and Insights

Major companies operating in the diabetic peripheral neuropathy market are focusing on technological innovations, such as NaV1.8 pain signal inhibitors, to provide patients with advanced, non-opioid treatments that improve pain management and overall quality of life. A NaV1.8 pain signal inhibitor is a specialized drug that blocks the NaV1.8 sodium channel, a key mediator of pain signals in sensory neurons, to provide relief from acute and neuropathic pain without relying on opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, announced advancements in its suzetrigine pain program, including initiating a Phase 3 pivotal program for treating pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has shown promising results in earlier studies and recently received Food and Drug Administration (FDA), a US-based federal agency breakthrough therapy designation for diabetic Peripheral Neuropathy (DPN)pain management.

What Are Latest Mergers And Acquisitions In The Diabetic Peripheral Neuropathy Market?

In December 2024, ElectroCore, Inc., a US-based medical technology company, acquired NeuroMetrix, Inc. for $26 million. With this acquisition, ElectroCore seeks to diversify its bioelectronic health and wellness offerings by integrating NeuroMetrix's Quell platform. This strategic move aims to expand its non-invasive, technology-driven solutions to manage chronic pain and address conditions such as diabetic peripheral neuropathy while enhancing its technological capabilities and increasing its market reach. NeuroMetrix, Inc. is a US-based healthcare company that develops and sells products to help diagnose and treat diabetic peripheral neuropathy (DPN).

Regional Outlook

North America was the largest region in the diabetic peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetic Peripheral Neuropathy Market?

The diabetic peripheral neuropathy market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical treatment services, and physical and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic peripheral neuropathy market also includes sales of pharmaceuticals, medical devices, nutritional supplements, and physical therapy tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetic Peripheral Neuropathy Market Report 2026?

The diabetic peripheral neuropathy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic peripheral neuropathy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.